ArticleFrontiers in pediatrics2020
Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Measurable Residual Disease.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Analysis of Antigen Expression in T-Cell Acute Lymphoblastic Leukemia by Multicolor Flow Cytometry: Implications for the Detection of Measurable Residual Disease.International journal of molecular sciences · 2025Article
- Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.Annals of hematology · 2024Article
- T-Cell Acute Lymphoblastic Leukemia-Current Concepts in Molecular Biology and Management.Biomedicines · 2021Review
- Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 20 institutions in 1 country.
Nerea Vega-GarcíaHaematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Sara Perez-JaumeDevelopmental Tumour Biology Laboratory, Institut de Recerca Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.
Elena Esperanza-CebolladaHaematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Clara Vicente-GarcésHaematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Montserrat TorrebadellHaematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Antonio Jiménez-VelascoHaematology and Hemotherapy Laboratory, Hospital Carlos Haya, Málaga, Spain.
Margarita OrtegaCytogenetics Unit, Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain.
Marta LlopMolecular Biology Unit, Clinical Analysis Service, La Fe University and Polytechnic Hospital, Valencia, Spain.
Lorea AbadPaediatric Hemato-Oncology Laboratory, Hospital Niño Jesús, Madrid, Spain.
José Manuel VagaceHaematology Laboratory, Hospital Materno Infantil, Badajoz, Spain.
Alfredo MinguelaImmunology Service, Clinic University Hospital Virgen de la Arrixaca (HCUVA) and Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Marta PratcoronaHaematology Laboratory, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Joaquín Sánchez-GarciaHematology Department, Hospital Reina Sofía, IMIBIC, UCO, Córdoba, Spain.
Clara B García-CalderónInstituto de Biomedicina de Sevilla (IBIS/Consejo Superior de Investigaciones Científicas (CSIC)/Centro de Investigación Biomédica en Red - Cáncer (CIBERONC)), Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Seville, Spain.
María Teresa Gómez-CasaresBiology and Molecular Haematology and Hemotherapy Service, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canarias, Spain.
Estela Martín-ClaveroHaematology-Cytology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Adela EscuderoTranslational Research in Pediatric Oncology Hematopoietic Transplantation and Cell Therapy, Institute of Medical and Molecular Genetics (INGEMM), Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Marta Riñón Martinez-GalloImmunology Laboratory, Hospital de Cruces, Bilbao, Spain.
Luz MuñozHaematology Laboratory, Hospital Parc Taulí, Sabadell, Spain.
María Rosario VelascoHaematology Department, Hospital Virgen de la Salud, Toledo, Spain.
Marina García-MorinPaediatric Hematology Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Albert CatalàDevelopmental Tumor Biology Group, Leukemia and Other Pediatric Hemopathies, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Antonia PascualHaematology Department, Hospital Carlos Haya, Málaga, Spain.
Pablo VelascoPediatric Hematology and Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
José Mª FernándezHaematology and Oncology Department, Hospital de La Fe, Valencia, Spain.
Alvaro LassalettaHaematology and Oncology Department, Hospital Niño Jesús, Madrid, Spain.
José Luis FusterPaediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca (HCUVA) and Instituto Murciano de Investigación Biosanitaria (IMIB), Murcia, Spain.
Isabel BadellPaediatric Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Águeda Molinos-QuintanaInstituto de Biomedicina de Sevilla (IBIS/Consejo Superior de Investigaciones Científicas (CSIC)/Centro de Investigación Biomédica en Red - Cáncer (CIBERONC)), Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Seville, Spain.
Antonio MolinésUnit of Hematology and Hemotherapy, H.U. Materno Infantil de Canarias, Canarias, Spain.
Pilar Guerra-GarcíaPaediatric Hemato-Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Antonio Pérez-MartínezTranslational Research in Pediatric Oncology Hematopoietic Transplantation and Cell Therapy, Institute of Medical and Molecular Genetics (INGEMM), Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Miriam García-AbósPediatric Onco-Hematology Department, Hospital Universitario Donostia, Donostia, Spain.
Reyes Robles OrtizPediatric Onco-Hematology Department, Complejo Hospitalario de Navarra, Navarra, Spain.
Sandra PisaPaediatric Hematology Department, Hospital Parc Taulí, Sabadell, Spain.
Rosa AdánHaematology and Oncology Department, Hospital de Cruces, Bilbao, Spain.
Cristina Díaz de HerediaPediatric Hematology and Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
José Luis DapenaDevelopmental Tumor Biology Group, Leukemia and Other Pediatric Hemopathies, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Susana RivesDevelopmental Tumor Biology Group, Leukemia and Other Pediatric Hemopathies, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Manuel Ramírez-OrellanaPaediatric Hemato-Oncology Laboratory, Hospital Niño Jesús, Madrid, Spain.
Mireia CamósHaematology Laboratory, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
Hospital Infantil Universitario Niño Jesús · ESHospital Sant Joan de Déu Barcelona · ESUniversitat de Barcelona · ESVall d'Hebron Hospital Universitari · ESDeleted InstitutionHospital de Cruces · ESHospital de Sant Pau · ESHospital Doctor José Molina Orosa · ESHospital La Paz Institute for Health Research · ESHospital Materno-Infantil · ESHospital Universitario 12 De Octubre · ESHospital Universitario Virgen del Rocío · ESInstitut de Recerca Sant Joan de DéuInstituto Murciano de Investigación Biosanitaria · ESComplejo Hospitalario de Navarra · ESDonostiako Unibertsitate Ospitalea · ESHospital General Universitario Gregorio Marañón · ESHospital Universitari i Politècnic La Fe · ESHospital Universitario de Gran Canaria Doctor Negrín · ESHospital Universitario Reina Sofía · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robust and applicable risk-stratifying genetic factors at diagnosis in pediatric T-cell acute lymphoblastic leukemia (T-ALL) are still lacking, and most protocols rely on measurable residual disease (MRD) assessment. In our study, we aimed to analyze the impact of
Indexed as
flow cytometrymeasurable (minimal) residual diseaseNOTCH1oncogeneticspediatricsrisk-factorsT-cell acute lymphoblastic leukemia
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.